Imagen de Portada

DECIDER-2: prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy : study protocol

Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of the combination of venetoclax (VEN) with azacitidine (AZA) or decitabine (DAC) in the European Union in 2021 for the treatment of patients with newly diagnosed AML who are ineligible...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Grishina, Olga (Autor) , Schmoor, Claudia (Autor) , Sellner, Caroline (Autor) , Hackanson, Björn (Autor) , Mikesch, Jan-Henrik (Autor) , Deligiannis, Iordanis (Autor) , Thol, Felicitas (Autor) , Crysandt, Martina (Autor) , Junghanss, Christian (Autor) , Runde, Volker (Autor) , Rosée, Paul La (Autor) , Teichmann, Lino Lars (Autor) , Al-Ali, Haifa Kathrin (Autor) , Sauer, Tim (Autor) , Germing, Ulrich (Autor) , Griesinger, Frank (Autor) , Lukic, Stefan (Autor) , Krauter, Jürgen (Autor) , Janjetovic, Snjezana (Autor) , Koch, Jan (Autor) , Staib, Peter (Autor) , Topaly, Julian (Autor) , de Wit, Maike (Autor) , Kraemer, Doris Maria (Autor) , Oelschläger, Lorenz (Autor) , Schnetzke, Ulf (Autor) , Schmah, Oliver (Autor) , Wessendorf, Swen (Autor) , Khandanpour, Cyrus (Autor) , Kündgen, Lukas (Autor) , Schwalenberg, Monika (Autor) , Heuser, Michael (Autor) , Ganser, Arnold (Autor) , Döhner, Hartmut (Autor) , Wäsch, Ralph (Autor) , Lübbert, Michael (Autor)
Formato: Article (Journal)
Lenguaje:inglés
Publicado: December 2026
In: BMC cancer
Year: 2026, Volumen: 26, Número: 1, Pages: 1-9
ISSN:1471-2407
DOI:10.1186/s12885-026-16617-8
Acceso en línea:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-026-16617-8
Enlace del recurso
Notas de Autor:Olga Grishina, Claudia Schmoor, Caroline Sellner, Björn Hackanson, Jan-Henrik Mikesch, Iordanis Deligiannis, Felicitas Thol, Martina Crysandt, Christian Junghanss, Volker Runde, Paul La Rosée, Lino Lars Teichmann, Haifa Kathrin Al-Ali, Tim Sauer, Ulrich Germing, Frank Griesinger, Stefan Lukic, Jürgen Krauter, Snjezana Janjetovic, Jan Koch, Peter Staib, Julian Topaly, Maike de Wit, Doris Maria Kraemer, Lorenz Oelschläger, Ulf Schnetzke, Oliver Schmah, Swen Wessendorf, Cyrus Khandanpour, Lukas Kündgen, Monika Schwalenberg, Michael Heuser, Arnold Ganser, Hartmut Döhner, Ralph Wäsch and Michael Lübbert
Descripción
Sumario:Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of the combination of venetoclax (VEN) with azacitidine (AZA) or decitabine (DAC) in the European Union in 2021 for the treatment of patients with newly diagnosed AML who are ineligible for induction chemotherapy has become the treatment backbone for older, medically non-fit AML patients. Based on in vitro priming of AML cells to all-trans retinoic acid (ATRA) by DAC, we had previously conducted a randomized phase II trial (DECIDER, AMLSG 14 − 09) in 200 elderly, non-fit AML patients on the effect of ATRA as add-on to DAC. Median overall survival (OS) was 8.2 months with ATRA versus 5.1 months without ATRA (hazard ratio, 0.65; 95% CI, 0.48 to 0.89; P = 0.006). Notably, ATRA did not add toxicity, the combination was active also in patients with adverse genetics, and prolonged time to treatment resistance. Investigating a triple combination of DAC, VEN and ATRA was a logical next step. This randomized double-blind phase III trial compares the efficacy of ATRA versus placebo as add-on to the backbone treatment (DAC and VEN) with respect to OS, objective best response, quality of life and safety. The accompanying translational research will contribute to identify molecular markers for drug efficacy and better tailoring epigenetic therapy.
Notas:Online veröffentlicht: 5. August 2026, Artikelversion: 5. August 2026
Gesehen am 03.09.2026
Descripción Física:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-026-16617-8

Ejemplares similares